China
China's liver cancer cases to hit 264,000 by 2034
China's liver cancer cases to hit 264,000 by 2034
It will account for roughly 71% of the projected 8MM incident cases.
5 days ago
China's internet healthcare pivots to AI disease management
New prescription rules favour compliant platforms as regulations tighten.
5 days ago
China’s 15th Five‑Year Plan elevates medtech, brain‑computer interfaces
AI adoption in medtech is also moving from policy to practice.
6 days ago
China to carry half of global hepatitis C burden by 2035, report says
Roughly 70% of acute hepatitis C infections progress to chronic infection.
China’s healthcare defies Hang Seng slump with 0.9% gain
Investor sentiment, however, weakened during the second quarter.
China's healthcare sector set for global breakout
Greater China completed 186 cross-border biotech out-licensing deals in 2025.
China healthcare lags Hong Kong and global markets in 2026
It posted the largest decline in price-to-earnings.
A+H dual listings signal China healthcare’s shift toward global expansion
Hong Kong serves as a key platform for global capital access.
China healthcare sector hit by regulation, biotech uncertainty
The sector stayed Overweight, supported by innovation and global deal activity.
China pushes expanded national maternity insurance systems in draft law
Several regions have already expanded coverage to flexible workers.
China’s healthcare index sinks 7.1% as investors pivot to tech AI
The sector’s stocks lag as AI inflows reshaped sector allocation patterns.
China healthcare firms offset policy pressure with global growth
Most major healthcare companies reported satisfactory 2025 financial results.
China Biopharma’s $56.7b deal boom signals pillar industry dominance
Out-licensing jumped 132% as sector becomes second-largest global hub.
Ping An Good Doctor projected to see 56% profit CAGR surge by 2027
Ali Health adjusted net profit forecast at 24% CAGR.
China captures 49% of global drug deals in 2025 amidst lower costs, faster timelines
This is an improvement from only 6% in 2020.
Strong pipeline, M&A activity could trigger rapid earnings for Greater China's healthcare firms: UOB
The industry is expected to become a key international player.
China commands 30% of global biopharma pipeline; drives Asia’s share to 43%
The country transitions from fast follower to global innovation frontrunner.
Most Read
1. India’s Ankura Hospitals opens 120-bed super speciality hospital in Indore 2. China’s 15th Five‑Year Plan elevates medtech, brain‑computer interfaces 3. Can Saudi insurers protect profits without owning healthcare providers? 4. China's liver cancer cases to hit 264,000 by 2034 5. China's internet healthcare pivots to AI disease managementResource Center
Read Here
Advertise
Sign Up
Partner Events
Event News
Demand was strong for AI-driven and digital healthcare solutions.
Commentary
AI drug discovery, GLP-1, and the next wave of Hong Kong biotech listings